On September 15, 2023 Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, reported the presentation of initial safety data from the ongoing Phase 1 clinical trial evaluating the recommended dose, safety and tolerability of Radspherin in patients with recurrent ovarian cancer at the 24th Congress of the European Society of Gynaecological Oncology (ESGO) being held at the Istanbul Congress Center in Istanbul, Türkiye from September 28 – October 1, 2023 (Press release, Oncoinvent, SEP 28, 2023, View Source [SID1234635520]). The presentation, titled "First Experience With Intra-Abdominal 224Radium-Labelled Microparticles (Radspherin) After Cytoreductive Surgery For Peritoneal Metastasis In Recurrent Epithelial Ovarian Cancer (Phase 1 Study)" will be presented on September 30, 2023 from 9:24 a.m. to 9:32 a.m. local time (5:24 a.m. ET).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Oncoinvent is proud to present safety data from our lead candidate, Radspherin at a major congress of the global gynecological cancer community. We believe this is an important first step as we advance the development of Radspherin as a new treatment for patients with advanced ovarian cancer," says CEO Anders Månsson.
Details of the presentation are as follows:
Session: MO3 Mini Oral Session – Ovarian Cancer
Presentation Title: First Experience With Intra-Abdominal 224Radium-Labelled Microparticles (Radspherin) After Cytoreductive Surgery For Peritoneal Metastasis In Recurrent Epithelial Ovarian Cancer (Phase 1 Study)
Presentation Board Number: 850
Presenting Author: Els Van Nieuwenhuysen, MD
Presentation Date and Time: September 30th, 2023, from 9:24 a.m. to 9:32 a.m. local time (5:24 a.m. ET)
The ongoing Phase 1 study is designed to evaluate the recommended dose, safety and tolerability of Radspherin injected intraperitoneally following secondary cytoreductive surgery. The safety interim analysis after completion of the dose-limiting toxicity (DLT) period demonstrated that Radspherin was well tolerated. The highest dose of 7 MBq was recommended following the completion of dose escalation of 1-2-4-7 MBq, as no DLT was observed.